Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Humans Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces

NCT01494844
View directory record Official record
Conditions
Respiratory Device Comfort
Interventions
Respiratory monitor patient interface.
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
20 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Jul 22, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

NCT02093221
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 35 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 22, 2026, 5:00 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Human Laboratory Study of Smokeless Tobacco Products

NCT01100216
View directory record Official record
Conditions
Smokeless Tobacco
Interventions
Nicotine Lozenge, Stonewall Dissolvable Tobacco Pieces, Camel Snus Frost, Skoal Wintergreen
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Jul 22, 2026, 5:00 AM EDT
Terminated Phase 2Phase 3 Interventional

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

NCT00042406
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Humax-CD4, Placebo
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
50
States / cities
Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54

NCT03882528
View directory record Official record
Conditions
Malaria,Falciparum
Interventions
Plasmodium falciparum malaria parasite
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Tests of Flu Vaccination Phone Messages

NCT03332992
View directory record Official record
Conditions
Influenza, Human
Interventions
Viral changes, Protect others, General intentions, Behavioral intentions, Accountability
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
7,206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 22, 2026, 5:00 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 22, 2026, 5:00 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Timed Aspirin Chronobiome Study

NCT03590821
View directory record Official record
Conditions
Healthy
Interventions
Aspirin 81 mg, Celecoxib 200mg capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 5:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Accuracy Performance Verification of the INVOS™ PM7100 System in Adults

NCT06581835
View directory record Official record
Conditions
Oxygen Saturation
Interventions
Observational
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jul 22, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

NCT02194998
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 5:00 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus

NCT00496158
View directory record Official record
Conditions
Chronic Hepatitis, Hepatitis B
Interventions
Clevudine, Adefovir
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Anaheim, California • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2009 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Jul 22, 2026, 5:00 AM EDT
Active, not recruiting Early Phase 1 Interventional

Transformation of Paralysis to Stepping

NCT04105114
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone, Non-invasive Spinal Cord Stimulation, Overground stepping, Gravity Neutral Device, Body Weight Supported Treadmill Training, Rolling Walker
Drug · Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 5:00 AM EDT
Recruiting Phase 2 Interventional

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

NCT07227233
View directory record Official record
Conditions
Breast Cancer
Interventions
A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2011 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Homologous Re-infection With Dengue 1 or Dengue 3

NCT05967455
View directory record Official record
Conditions
Dengue
Interventions
Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC), Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Mass Balance Study of HMS5552 in Healthy Subjects

NCT03158506
View directory record Official record
Conditions
Healthy Subject
Interventions
HMS5552
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

NCT02886884
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
20 million Allogeneic Mesenchymal Human Stem Cells, 100 million Allogeneic Mesenchymal Human Stem Cells
Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Jul 22, 2026, 5:00 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

B-19 Parvovirus Vaccine Study

NCT00379938
View directory record Official record
Conditions
Parvovirus B19 Infection
Interventions
VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2011 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

NCT03816878
View directory record Official record
Conditions
Influenza
Interventions
H5N1 pISV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 4 Interventional Results available

FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care

NCT03694808
View directory record Official record
Conditions
Flu
Interventions
Fluad Vaccine, Fluzone HD Vaccine
Drug
Lead sponsor
David H. Canaday
Other
Eligibility
65 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Not applicable Interventional

Way to Cure HCV Adherence

NCT02472925
View directory record Official record
Conditions
Hepatitis C
Interventions
MedSignals Pill Box
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Jul 22, 2026, 5:00 AM EDT